Form 4: Amphastar Pharmaceuticals Executive Rong Zhou Reports Stock Transactions

Senior EVP Rong Zhou of Amphastar Pharmaceuticals reports the acquisition and disposal of company stock, including transactions related to employee stock options and the employee stock purchase plan.

Summary

• On August 26, 2024, Rong Zhou, Senior EVP of Production Center at Amphastar Pharmaceuticals, engaged in transactions involving the company's common stock.
• Zhou acquired 4,000 shares at $14.95 through the exercise of employee stock options.
• Concurrently, Zhou disposed of 4,000 shares at $48.35.
• Following these transactions, Zhou directly owns 118,388 shares of common stock.
• Zhou also has indirect ownership of 99,668 shares through the Zhou Family Trust and 5,000 shares held by their spouse.
• Zhou also owns options to purchase 9,893 shares of common stock at an exercise price of $14.95.

Sentiment

Score: 5

Explanation: Neutral sentiment. The transactions are routine and do not indicate a strong positive or negative outlook.

Positives

• The exercise of employee stock options and participation in the employee stock purchase plan indicates confidence in the company's future.

Negatives

• The sale of 4,000 shares could be interpreted negatively, although it is common for executives to diversify their holdings.

Risks

• Executive stock transactions can sometimes signal a change in company outlook, although this is not necessarily the case here.

Future Outlook

The document does not contain explicit forward-looking statements, but the executive's stock transactions provide insight into their current view of the company's value.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for signals about a company's prospects.

Comparison to Industry Standards

• Executive compensation and stock ownership are typical components of corporate governance in publicly traded companies like Amphastar Pharmaceuticals.
• Comparing Rong Zhou's stock ownership and transaction history to those of executives at comparable pharmaceutical companies (e.g., Teva Pharmaceutical Industries, Mylan, or Hikma Pharmaceuticals) could provide a benchmark for assessing the significance of these transactions.
• Industry standards often involve a mix of salary, stock options, and restricted stock units to align executive interests with shareholder value.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, depending on how they are interpreted.

Key Dates